CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-02 | Patel Anish Chief Operating Officer | Sale 10b5-1 | −11,000 | $15.00 | $165K | 22,097 |
| 2024-01-02 | Hohl Benjamin Chief Financial Officer | Option exercise 10b5-1 | +9,383 | $2.48 | $23K | 9,383 |
| 2024-01-02 | Hohl Benjamin Chief Financial Officer | Sale 10b5-1 | −9,383 | $15.01 | $141K | 0 |
| 2024-01-02 | Hohl Benjamin Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −9,383 | 249,120 | ||
| 2023-12-29 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2023-12-29 | Lyssikatos Joseph P Chief Scientific Officer | Sale 10b5-1 | −9,151 | $14.13 | $129K | 2,849 |
| 2023-12-29 | Lyssikatos Joseph P Chief Scientific Officer | Sale 10b5-1 | −2,849 | $14.78 | $42K | 0 |
| 2023-12-29 | Lyssikatos Joseph P Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 296,550 | ||
| 2023-12-29 | Patel Anish Chief Operating Officer | Sale 10b5-1 | −20 | $15.00 | $300 | 33,097 |
| 2023-12-29 | Hohl Benjamin Chief Financial Officer | Option exercise 10b5-1 | +20 | $2.48 | $50 | 20 |
| 2023-12-29 | Hohl Benjamin Chief Financial Officer | Sale 10b5-1 | −20 | $15.00 | $300 | 0 |
| 2023-12-29 | Hohl Benjamin Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −20 | 258,503 | ||
| 2023-12-28 | Patel Anish Chief Operating Officer | Sale 10b5-1 | −2,520 | $15.08 | $38K | 33,117 |
| 2023-12-28 | Hohl Benjamin Chief Financial Officer | Option exercise 10b5-1 | +2,467 | $2.48 | $6K | 2,467 |
| 2023-12-28 | Hohl Benjamin Chief Financial Officer | Sale 10b5-1 | −2,467 | $15.07 | $37K | 0 |
| 2023-12-28 | Hohl Benjamin Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −2,467 | 258,523 | ||
| 2023-12-26 | Kintz Samuel President and CEO | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2023-12-26 | Kintz Samuel President and CEO | Sale 10b5-1 | −12,000 | $14.64 | $176K | 0 |
| 2023-12-26 | Kintz Samuel President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 296,550 | ||
| 2023-12-26 | Patel Anish Chief Operating Officer | Sale 10b5-1 | −102 | $15.01 | $2K | 35,637 |
Page 27 of 37 · 724 trades